entinostat (SNDX-275) - Kyowa Hakko Kirin, Syndax
Entinostat: Interim OS analysis from P3 E2112 trial (NCT02115282) in combination with exemestane for advanced HR+ breast cancer in Q4 2019 (Syndax) - May 7, 2019 - Q1 2019 Results: Final OS analysis from P3 E2112 trial in combination with exemestane for advanced HR+ breast cancer in Q2 2020 
P3 data
http://ir.syndax.com/events-presentations
 
May 7, 2019
 
 
90f1443c-db62-4379-9d2b-eb968f5f0fab.png